SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Ruben A. Mesa, Jean‐Jacques Kiladjian, John Vincent Catalano et al. · Journal of Clinical Oncology · 2017
Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with myelofibrosis. Patients and Methods Patients (N = 432) with high risk or intermediate-2 risk or symptomatic intermediate-1 risk myelofibrosis were randomly assigned to receive 24 weeks of treatment with momelotinib 200 mg once daily or ruxolitinib 20 mg twice a day (or per label), after which all patients could receive open-label momelotinib. The primary end point was a ≥ 35% reduction in spleen volume at 24 weeks of therapy. Secondary end points were rates of symptom response and effects on RBC transfusion requirements. Results A ≥ 35% reduction in spleen volume at week 24 was achieved by a similar proportion of patients in both treatment arms: 26.5% of the momelotinib group and 29% of the ruxolitinib group (noninferior; P = .011). A ≥ 50% reduction in the total symptom score was observed in 28.4% and 42.2% of patients who received momelotinib and ruxolitinib, respectively, indicating that noninferiority was not met ( P = .98). Transfusion rate, transfusion independence, and transfusion dependence were improved with momelotinib (all with nominal P ≤ .019). The most common grade ≥ 3 hematologic abnormalities in either group were thrombocytopenia and anemia. Grade ≥ 3 infections occurred in 7% of patients who received momelotinib and 3% of patients who received ruxolitinib. Treatment-emergent peripheral neuropathy occurred in 10% of patients who received momelotinib (all grade ≤ 2) and 5% of patients who received ruxolitinib (all grade ≤ 3). Conclusion In JAKi-naïve patients with myelofibrosis, 24 weeks of momelotinib treatment was noninferior to ruxolitinib for spleen response but not for symptom response. Momelotinib treatment was associated with a reduced transfusion requirement.
Cited by 387 works. doi:10.1200/jco.2017.73.4418
Authors
- Ruben A. Mesa
- Jean‐Jacques Kiladjian
- John Vincent Catalano
- Timothy Devos
- Miklós Egyed
- Andrzei Hellman
- Donal P. McLornan
- Kazuya Shimoda
- Elliott F. Winton
- Ronald L. Dubowy
- Julia D. Maltzman
- Francisco Cervantes
- Jason R. Gotlib
References
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
- Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
- Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
- JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis